This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Cigna (CI) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $360.37, moving -0.19% from the previous trading session.
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
5 Low Price-to-Sales Stocks Poised to Race up the Charts
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like KBH, AMG, CI, BBSI and JAKK hold promise.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Top Research Reports for Walmart, Linde & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Linde plc (LIN) and International Business Machines Corporation (IBM).
Acadia (ACHC) Starts Construction of Malden's JV Facility
by Zacks Equity Research
Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.
Here's How Much a $1000 Investment in Cigna Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Cigna (CI) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Cigna (CI) reachead $363.34 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Why Cigna (CI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Brokers Suggest Investing in Cigna Group (CI): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Cigna Group (CI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
S&P 500 Achieves a New Milestone: Top 5 Non-Tech Picks
by Nalak Das
We have narrowed our search to five non-tech S&P 500 stocks that have provided double-digit returns year to date. These are: CI, RL, PH, ETN, EBAY.
UnitedHealth (UNH) to Roll Out Medical Claims Software Soon
by Zacks Equity Research
UnitedHealth (UNH) assists care providers with more than $2 billion through several initiatives to mitigate the cash flow crunch arising from the cyberattack.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
Evaluating Molina Healthcare's (MOH) Future View: Hold or Fold?
by Zacks Equity Research
Molina Healthcare's (MOH) top line is poised to gain from rising premium revenues and investment income.
Cigna (CI) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Cigna (CI) closed at $352.63, indicating a +0.16% shift from the previous trading day.
CI or HUM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Zacks.com featured highlights PagSeguro Digital, Affiliated Managers, Cigna, Barrett Business Services and Fidelis Insurance
by Zacks Equity Research
PagSeguro Digital, Affiliated Managers, Cigna, Barrett Business Services and Fidelis Insurance have been highlighted in this Screen of The Week article.
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
by Derek Lewis
The market has enjoyed a fantastic run in 2024, building nicely on last year???s gains. But not all have joined the party, specifically these three. Deep in the red year-to-date, are they worth a look?
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
5 Low Price-to-Sales Stocks to Fetch Solid Portfolio Gains
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PAGS, AMG, CI, BBSI and FIHL hold promise.